Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 5Phase 3 4Phase 1 3Phase NA 1Phase 4 1Phase 2/3 1

Status

Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1

Conditions

Solid Neoplasm 1Sarcoma 1Neoplasm Metastasis 1

Interventions

pembrolizumab 257Cyclophosphamide 241Specimen Handling 198fludarabine 173Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 119Carboplatin 97Radiotherapy 92Paclitaxel 85venetoclax 82Cisplatin 80Gemcitabine 79fludarabine phosphate 78Injections 68Ipilimumab 64Dexamethasone 61atezolizumab 59Bevacizumab 58Cetuximab 57Radiation 55Fluorouracil 55Azacitidine 55durvalumab 54Radiosurgery 52Temozolomide 47Rituximab 44Oxaliplatin 44Irinotecan 43Docetaxel 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × pazopanib × 1 year × Clear all
NCT01642017 2026-04-14

VOTRAGE

Institut Claudius Regaud

Phase 1 Terminated
18 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01552356 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled

Solid Neoplasm

NCT07444619 2026-03-03

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
18 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡